Vranken Jan H, Troost Dirk, de Haan Peter, Pennings Fritz A, van der Vegt Marinus H, Dijkgraaf Marcel G W, Hollmann Markus W
Pain Relief Unit, Department of Anesthesiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Anesthesiology. 2006 Oct;105(4):813-8. doi: 10.1097/00000542-200610000-00028.
Ketamine and S(+)-ketamine have been advocated for neuraxial use in the management of postoperative pain and severe intractable pain syndromes unresponsive to opioid escalation. Although clinical experience has accumulated with S(+)-ketamine, safety data on toxicity in the central nervous system after neuraxial administration of S(+)-ketamine are conflicting. In this study, neurologic and toxicologic effects on the spinal cord from repeated daily intrathecal administration of commercially available, preservative-free S(+)-ketamine were evaluated against placebo in a randomized, blinded design.
Eighteen white New Zealand rabbits were assigned to two groups receiving either 0.5 ml intrathecal S(+)-ketamine, 0.5% solution (12 rabbits), or 0.5 ml saline (6 rabbits) once a day for 7 consecutive days. During general anesthesia, an intrathecal catheter was placed between the fifth and sixth spinous processes (lumbar). Neurologic (according to Tarlov criteria) and histopathologic assessments were performed after 7 days of treatment.
Postmortem investigation of the spinal cord and nerve roots revealed histopathologic lesions suggestive of toxic damage in 11 rabbits, from the group of 12 animals receiving S(+)-ketamine. These results were significantly different compared with 5 control animals (no histologic changes observed). There was no significant difference in neurologic status between the two groups after 7 days of intrathecal treatment.
The authors conclude that repeated intrathecal administration of preservative-free S(+)-ketamine in a clinically relevant concentration and dosage has, considering the extent and severity of the lesions, a toxic effect on the central nervous system of rabbits.
氯胺酮和S(+)-氯胺酮已被提倡用于椎管内给药,以管理术后疼痛和对阿片类药物剂量增加无反应的严重顽固性疼痛综合征。尽管已有关于S(+)-氯胺酮的临床经验积累,但S(+)-氯胺酮椎管内给药后中枢神经系统毒性的安全数据存在矛盾。在本研究中,采用随机、双盲设计,将市售无防腐剂的S(+)-氯胺酮每日重复鞘内给药对脊髓的神经和毒理学影响与安慰剂进行比较评估。
18只白色新西兰兔被分为两组,连续7天每天接受一次0.5ml鞘内注射S(+)-氯胺酮0.5%溶液(12只兔)或0.5ml生理盐水(6只兔)。在全身麻醉期间,在第五和第六棘突(腰部)之间放置一根鞘内导管。治疗7天后进行神经学(根据塔尔洛夫标准)和组织病理学评估。
对脊髓和神经根的尸检发现,在接受S(+)-氯胺酮的12只动物组中,有11只兔存在提示毒性损伤的组织病理学病变。与5只对照动物(未观察到组织学变化)相比,这些结果有显著差异。鞘内治疗7天后,两组的神经学状态无显著差异。
作者得出结论,考虑到病变的范围和严重程度,以临床相关浓度和剂量重复鞘内注射无防腐剂的S(+)-氯胺酮对兔中枢神经系统具有毒性作用。